All News
INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis
The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.
Read Article
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.
Read Article
Limited Efficacy of Muscle Relaxants for Chronic Pain
A systematic review of long-term muscle relaxant use for chronic pain suggests they may be effective in treating trigeminal neuralgia, cramps, and neck pain, but not fibromyalgia, low back pain, and other pain syndromes.
Read Article
Danish cross-sectional survey 12 713 Inflam arthritis (RA, PsA, SpA) pts & found lonliness in one-third (RA 32%; 36% in PsA & SpA) and highest in SpA w/ depression (66%). Loneliness was correlated w/ disease activity. https://t.co/Q3IswbIwe6 https://t.co/GNohOkkmEw
Dr. John Cush RheumNow ( View Tweet)
Full read overview of ILD & its Clinical Course inRheumatoid Arthritis. Metanalysis of 22 reports shows 6-19% of RA have ILD on HRCT. Article discusses early onset, progression and the monitoring and management of RA-ILD https://t.co/mqexPcruni https://t.co/One7XYn4wX
Dr. John Cush RheumNow ( View Tweet)
Analysis of 5 Nordic registries & 29,478 RA & 10,919 PsA pts initiating 1st bDMARD,s
(& 362,087 pop controls). Incident ILD was higher in RA (HR 9.7) & PsA (4.4). but MTX co-use (vs non-use) did not incr ILD in RA (HR 0.9; 0.7, 1.2) or PsA (HR 1.0) https://t.co/xY8COh85Bw https://t.co/weJGirfhDX
Links:
Dr. John Cush RheumNow ( View Tweet)
🌟 ACUTE OPTIC NEURITIS - Differentials https://t.co/eE1Kbnmqc1
Dr. Akhil 🇮🇳 DrAkhilX ( View Tweet)
🌟 ASAS researchers recommend using axSpA as the overarching term for axial spondyloarthritis. They prefer radiographic-axSpA over ankylosing spondylitis. These changes aim to standardize terminology and improve clarity in diagnosis and treatment.
https://t.co/0IhvwPOfm2
#ASAS https://t.co/H8ummkNmEj
Links:
ASAS Official_ASAS ( View Tweet)
Congratulations to Dr. Sebastian Sattui on his new @NIHAging R03: "Prevalence and Impact of frailty in older adults with polymyalgia rheumatica"! 🎉🎊🎉 https://t.co/JRzr4cZZhg
PittDeptofMed PittDeptofMed ( View Tweet)
Treatment of Rheumatoid Arthritis (RA) associated Interstitial lung disease #ILD
2023 ACR/Chest Guideline
#Rheumatology #MedTwitter https://t.co/hoW88BL2E2
Ask The Rheumatologist LastManStand85 ( View Tweet)
Antidepressants for Pain are Weakly Effective
University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence.
https://t.co/ln5UguleUv https://t.co/CwZeHi3xWK
Dr. John Cush RheumNow ( View Tweet)
TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein… https://t.co/1NYgYtYKIr https://t.co/fMMy2DzSxN
Dr. John Cush RheumNow ( View Tweet)
FDA decision explained on why they modified its rule on #Biosimilar interchangeability. Approved 15 yrs ago, now there are 50 Biosimilars in USA. Switching (interchangeability) studies are no longer needed based on the FDA experience over last 8 years. https://t.co/vpmgdVeDwz https://t.co/UAWnFQxugl
Dr. John Cush RheumNow ( View Tweet)
Neoself-antigens are targeted by autoreactive T cells clonally expanded in SLE. Neoself-antigen presentation results in clonally expanded neoself-reactive T cells, leading to the development of lupus-like disease in mice. https://t.co/iFXNLNRxO5 https://t.co/9TEJUqfEbo
Dr. John Cush RheumNow ( View Tweet)
Fasenra (benralizumab, an anti-IL-5 mAb) has been FDA approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA); approval based on MANDARA trial - H2H noninferior to mepolizumab at remission https://t.co/5tAPolUItK https://t.co/VHCNjACThw
Dr. John Cush RheumNow ( View Tweet)
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis
A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).
https://t.co/i2w4RbGd5f https://t.co/5PD6pYB5vm
Dr. John Cush RheumNow ( View Tweet)
Full read review of Neonatal lupus syndrome - caused by pathogenic maternal autoAbs (SSA, SSB) in fetal circulation. Mild Sxs in 25%, severe Sxs are rare; Heart block in up to 2% of neonates born to mothers with positive antibodies. https://t.co/iH4MBRGvg1 https://t.co/kXxIeQC47m
Dr. John Cush RheumNow ( View Tweet)
BSR Guidelines for Systemic Sclerosis Management
The BSR has updated its 2015 guidelines for the management of patients with SSc based on published evidence, systematic literature review and expert opinion.
https://t.co/HdQrK4TKGI https://t.co/O6FeaelWZV
Dr. John Cush RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/4fgkNJeO4i https://t.co/Z2lDloBzrI
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of JAKi in ILD (7 studies, 183 pts) showed increases in FVC (2 %), DLCO (3.1%) & improved Thoracic HRCT of 11%; only 5% had worsening of their ILD. Risk of ILD w/ JAKi was low ( 0.20/1000 PY) w rates similar to abatacept & rituximab https://t.co/UDJ1ZvtGhh https://t.co/WTQS67yDyl
Links:
Dr. John Cush RheumNow ( View Tweet)